Dupilumab Administration in the Patient with Severe Eosinophilic Esophagitis Combined with T2-Associated Diseases: Case Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Case study shows dupilumab enhances symptom relief in eosinophilic esophagitis and atopic dermatitis, suggesting its therapeutic potential.

Dupilumab reduced eosinophilic infiltration and symptoms in a child with severe eosinophilic esophagitis.
Significant improvement was observed within 3 months, with complete remission of atopic dermatitis.
Standard therapies were ineffective before initiating dupilumab, indicating a need for novel treatment options.
No side effects were reported during dupilumab therapy, promoting its safety in managing T2-associated diseases.

Vyazankina et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Case study shows dupilumab enhances symptom relief in eosinophilic esophagitis and atopic dermatitis, suggesting its therapeutic potential.